{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["36(3)"],"submitter":["Gangwani MK"],"pubmed_abstract":["<h4>Background</h4>Crohn's disease is a relapsing disease that often requires operative management. Prevention of postoperative recurrence (POR) is critical to maintain remissions. Biologic agents have proven to be most successful in remission maintenance. We made a direct head-to-head comparison of the 2 anti-tumor necrosis factor agents, infliximab (IFX) and adalimumab (ADA), to compare endoscopic and clinical POR of Crohn's disease.<h4>Methods</h4>We conducted a comprehensive literature search in 7 databases, including Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, KCI-Korean Journal Index, SciELO, and Global Index Medicus. Odds ratios (OR) were calculated with 95% confidence intervals (CI) and P-values (<0.05 considered significant). We"],"journal":["Annals of gastroenterology"],"pagination":["293-299"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10152807"],"repository":["biostudies-literature"],"pubmed_title":["Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn's disease: a systematic review and meta-analysis."],"pmcid":["PMC10152807"],"pubmed_authors":["Dahiya DS","Ahmed Z","Aziz M","Kobeissy A","Gangwani MK","Lee-Smith W","Kamal F","Nawras M","Karna R","Alastal Y","Sohail AH","Priyanka F","Rani A"],"additional_accession":[]},"is_claimable":false,"name":"Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn's disease: a systematic review and meta-analysis.","description":"<h4>Background</h4>Crohn's disease is a relapsing disease that often requires operative management. Prevention of postoperative recurrence (POR) is critical to maintain remissions. Biologic agents have proven to be most successful in remission maintenance. We made a direct head-to-head comparison of the 2 anti-tumor necrosis factor agents, infliximab (IFX) and adalimumab (ADA), to compare endoscopic and clinical POR of Crohn's disease.<h4>Methods</h4>We conducted a comprehensive literature search in 7 databases, including Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, KCI-Korean Journal Index, SciELO, and Global Index Medicus. Odds ratios (OR) were calculated with 95% confidence intervals (CI) and P-values (<0.05 considered significant). We","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May-Jun","modification":"2025-04-27T03:15:49.789Z","creation":"2025-02-19T02:25:51.481Z"},"accession":"S-EPMC10152807","cross_references":{"pubmed":["37144019"],"doi":["10.20524/aog.2023.0786"]}}